Incyte (NASDAQ:INCY), founded in 2002 and headquartered in Wilmington, Delaware, is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies in oncology and inflammation. The company has established a reputation for its targeted approach to drug development, focusing on molecular pathways that regulate cellular growth and immune responses. Incyte’s research-driven model seeks to address unmet medical needs by advancing compounds through preclinical studies into late-stage clinical trials and regulatory approval.
The company’s flagship product, Jakafi (ruxolitinib), was the first selective inhibitor of the Janus kinase (JAK) pathway to gain approval in the United States and Europe. Jakafi is indicated for the treatment of myelofibrosis and polycythemia vera, and has become a cornerstone therapy in these rare blood disorders. Beyond Jakafi, Incyte’s portfolio includes additional oncology and inflammatory candidates, encompassing small molecules and biologics that target epigenetic modifiers, immune checkpoints and growth factor receptors.
Incyte maintains a global presence, with commercial operations in North America, Europe and Asia. The company collaborates with major pharmaceutical partners to broaden access to its therapies, leveraging strategic alliances for regulatory filings, manufacturing and marketing. Incyte’s clinical pipeline spans multiple tumor types and autoimmune conditions, underscoring its commitment to advancing precision medicine across diverse patient populations.
Under the leadership of President and Chief Executive Officer Hervé Hoppenot, Incyte continues to invest in early-stage research and external innovation through collaborations and licensing agreements. The executive team, composed of experienced drug developers and industry veterans, guides Incyte’s efforts to expand its pipeline, pursue regulatory milestones and ultimately deliver new treatment options for patients worldwide.
